Interleukin-1 beta inhibition with canakinumab, when added to concurrent chemoradiotherapy and durvalumab, shows favorable progression-free survival in the phase I/II CHORUS trial for unresectable stage III non-small cell lung cancer. The reported 24-month PFS rate of 67% comes from an early-stage safety-and-activity design. The combination targets an inflammatory pathway implicated in tumor progression and treatment response, aligning IL-1 biology with current checkpoint-containing thoracic regimens. For patients with stage III disease, where cure rates remain modest and systemic control is a persistent challenge, the signal expands the menu of investigational add-ons. Future work will need to define comparative effectiveness versus standard of care, characterize safety trade-offs, and identify any responders using inflammatory or tumor microenvironment biomarkers.